News & Updates

Intranasal esketamine, administered at two fixed doses as monotherapy for treatment-resistant depression (TRD), has demonstrated robust and rapid efficacy in a phase IV double-blind, placebo-controlled randomized trial.

Attention-deficit/hyperactivity disorder (ADHD) medications are associated with reduced risks of several serious real-world outcomes, but the magnitude of these associations has decreased alongside rising prescription rates, a nationwide study has shown.

Depression and the use of SSRIs appear to significantly contribute to an individual’s sexual functioning, distress, and pleasure, according to a study.

Researchers from the University of Hong Kong (HKU) have identified lithium level thresholds associated with risks of hypothyroidism, hyperthyroidism, and stage ≥3 chronic kidney disease (CKD). This provides empirical evidence that can facilitate the development of clinical guidelines for lithium treatment in bipolar disorder.